ISABEL MAREY-SEMPER

Corporate Board Profile

Tech Score: 43/100

← Back to All Directors

Software Technology Evidence

3 mention(s) identify ISABEL MAREY-SEMPER as having software/technology expertise.

Company Filing Date Evidence Reason
APTARGROUP, INC. 2019-03-22 Ms. Marey-Semper was a member of the Executive Committee of L'Oréal S.A. (personal care company and world's largest cosmetic company), in charge of Communications and Public Affairs, from July 2015 to December 2017. Prior to this, Ms. Marey-Semper served from 2011 to 2015 as Vice President and Head, Advanced Research at L'Oréal. Prior to joining L'Oréal, Ms. Marey-Semper served in executive positions at established industrial companies such as Compagnie de Saint-Gobain S.A. (a Euronext-listed French multinational manufacturer and distributor of building materials) and Group PSA Peugeot Citroën (a Euronext-listed French multinational manufacturer of automobiles and motorcycles). Ms. Marey-Semper is a director of the Imagine Institute (institute for medical research and treatment of genetic diseases), the Inria Foundation (research foundation dedicated to digital science and technology) and Damae Medical (a medical company focused on diagnosing skin tumors without the need for a biopsy). Ms. Marey-Semper was a director of Rexel (a Euronext-listed French distributor of electrical supplies) from 2014 to 2016. Ms. Marey-Semper has experience as Vice President and Head of Advanced Research at L'Oréal and is a director of the Inria Foundation, a research foundation dedicated to digital science and technology, indicating a software-related technical background.
APTARGROUP, INC. 2023-03-24 Ms. Marey-Semper has a PhD in neuropharmacology, was Vice President and Head of Advanced Research at L’Oréal, and is a key contributor to France 2030 and serves on the board of the Inria Foundation. Has a PhD in neuropharmacology and was Head of Advanced Research at L’Oréal; serves on the board of the Inria Foundation, which is dedicated to digital science and technology, indicating a strong technical and scientific background.
APTARGROUP, INC. 2024-03-22 Ms. Marey-Semper currently serves as an independent director of the Imagine Institute (institute for medical research and treatment of genetic diseases) and the Inria Foundation (research foundation dedicated to digital science and technology). Ms. Marey-Semper is also a key contributor to France 2030, the French government Investment Plan aiming at sustainably transforming key sectors through research, innovation and industrial investment. Ms. Marey-Semper is a knight of the National Order of the Legion of Honour. Ms. Marey-Semper has a PhD in neuropharmacology and a Masters in Business Administration. Ms. Marey-Semper has a PhD in neuropharmacology and is a key contributor to France 2030, a government investment plan focused on research, innovation, and industrial investment in digital science and technology, indicating a technical background relevant to software and programming.

APTARGROUP, INC.

Filing Date Source Excerpt
2019-03-22 Ms. Marey-Semper was a member of the Executive Committee of L'Oréal S.A. (personal care company and world's largest cosmetic company), in charge of Communications and Public Affairs, from July 2015 to December 2017. Prior to this, Ms. Marey-Semper served from 2011 to 2015 as Vice President and Head, Advanced Research at L'Oréal. Prior to joining L'Oréal, Ms. Marey-Semper served in executive positions at established industrial companies such as Compagnie de Saint-Gobain S.A. (a Euronext-listed French multinational manufacturer and distributor of building materials) and Group PSA Peugeot Citroën (a Euronext-listed French multinational manufacturer of automobiles and motorcycles). Ms. Marey-Semper is a director of the Imagine Institute (institute for medical research and treatment of genetic diseases), the Inria Foundation (research foundation dedicated to digital science and technology) and Damae Medical (a medical company focused on diagnosing skin tumors without the need for a biopsy). Ms. Marey-Semper was a director of Rexel (a Euronext-listed French distributor of electrical supplies) from 2014 to 2016.
2020-03-27 Ms. Marey-Semper was a member of the Executive Committee of L’Oréal S.A. (personal care company and world’s largest cosmetic company), in charge of Communications and Public Affairs, from July 2015 to December 2017. Prior to this, Ms. Marey-Semper served from 2011 to 2015 as Vice President and Head, Advanced Research at L’Oréal.
2021-03-26 Ms. Marey-Semper was a member of the Executive Committee of L’Oréal S.A. in charge of Communications and Public Affairs, and a director of the Inria Foundation (research foundation dedicated to digital science and technology).
2022-03-25 Ms. Marey-Semper currently serves as a senior advisor to Jolt Capital (a technology related private equity firm). She was a member of the Executive Committee of L’Oréal S.A. ... Ms. Marey-Semper has a PhD in neuropharmacology.
2023-03-24 Ms. Marey-Semper has a PhD in neuropharmacology, was Vice President and Head of Advanced Research at L’Oréal, and is a key contributor to France 2030 and serves on the board of the Inria Foundation.
2024-03-22 Ms. Marey-Semper currently serves as an independent director of the Imagine Institute (institute for medical research and treatment of genetic diseases) and the Inria Foundation (research foundation dedicated to digital science and technology). Ms. Marey-Semper is also a key contributor to France 2030, the French government Investment Plan aiming at sustainably transforming key sectors through research, innovation and industrial investment. Ms. Marey-Semper is a knight of the National Order of the Legion of Honour. Ms. Marey-Semper has a PhD in neuropharmacology and a Masters in Business Administration.
2025-03-28 Dr. Marey-Semper has served as the President of DOXANANO, a startup biotechnology research and development company... Dr. Marey-Semper has a PhD in neuropharmacology from Sorbonne Université and a Masters in Business Administration.

Data sourced from SEC filings. Last updated: 2025-10-12